Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPANE: Propranolol and Pembrolizumab in Advanced Angiosarcoma and UPS
2024-513727-16-00Phase 2Authorised
- Sponsor
- Capital Region of Denmark
- Start
- May 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and propranolol in angiosarcoma and Malignant Fibrous Histiocytoma (MFH), sponsored by Capital Region of Denmark. Primary endpoint: Percentage of patients alive with CR, PR and SD at 3 months. Planned start May 2024; status: authorised.
02
Drugs
pembrolizumabpropranolol
03
Conditions
angiosarcomaMalignant Fibrous Histiocytoma (MFH)
Beyond the preview
Go deeper on 2024-513727-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513727-16-00.